How an Unproven Alzheimer’s Drug Got Approved

Though some of its own senior officials said there was little evidence of benefit for patients, the F.D.A. nonetheless greenlighted Biogen’s Aduhelm, or aducanumab.

from NYT > Technology https://ift.tt/3imHC2y
via IFTTT

Share on Google Plus

About digital manu

This is a short description in the author block about the author. You edit it by entering text in the "Biographical Info" field in the user admin panel.